Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by 1H nuclear magnetic resonance-based metabonomic profiles

被引:79
作者
Zhang, Lin [1 ]
Jin, Haifeng [1 ]
Guo, Xuegang [1 ]
Yang, Zhao [1 ]
Zhao, Lina [1 ]
Tang, Shanhong [1 ]
Mo, Ping [1 ]
Wu, Kaichun [1 ]
Nie, Yongzhan [1 ]
Pan, Yanglin [1 ]
Fan, Daiming [1 ]
机构
[1] Fourth Mil Med Univ, State Key Lab Canc Biol, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
NMR; Metabonomics; Pancreatic cancer; Chronic pancreatitis; Biomarker; HDL CHOLESTEROL; SPECTROSCOPY; CARCINOMA; DIAGNOSIS; DISEASE; LIPIDS; SERUM; RISK;
D O I
10.1016/j.clinbiochem.2012.05.012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: To develop a noninvasive and accessible diagnostic method for pancreatic cancer (PC). Design and methods: We presented a metabolomic method, pattern recognition techniques applied to H-1 nuclear magnetic resonance (H-1 NMR) spectra, to investigate the plasma metabolites obtained from 19 patients with PC, 20 patients with chronic pancreatitis (CP) and 20 healthy individuals. Results: Metabolic changes associated with PC included abnormal amino acid and lipid metabolism, and possible multiple metabolic syndrome. PC elevated plasma levels of N-acetyl glycoprotein (NAG), dimethylamine (DMA), very low density lipoprotein (VLDL), and acetone, and reduced levels of 3-hydroxybutyrate, lactate, high density lipoprotein (HDL), low density lipoprotein (LDL), citrate, alanine, glutamate, glutamine, histidine, isoleucine, lysine, and valine. These metabolites could be a biomarker group for PC that distinguishes between PC and CP patients and healthy individuals. Conclusions: NMR-based metabonomic strategy appears as a promising approach for distinguishing pancreatic cancer and identifying new strategies for prevention or therapy in the clinical practice. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1064 / 1069
页数:6
相关论文
共 33 条
[1]  
[Anonymous], 2001, NIH PUBL
[2]   HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].
Barter, Philip ;
Gotto, Antonio M. ;
LaRosa, John C. ;
Maroni, Jaman ;
Szarek, Michael ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Bittner, Vera ;
Fruchart, Jean-Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310
[3]   Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics [J].
Bathe, Oliver F. ;
Shaykhutdinov, Rustem ;
Kopciuk, Karen ;
Weljie, Aalim M. ;
Mckay, Andrew ;
Sutherland, Francis R. ;
Dixon, Elijah ;
Dunse, Nicole ;
Sotiropoulos, Dina ;
Vogel, Hans J. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (01) :140-147
[4]   Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma [J].
Beger, Richard D. ;
Schnackenberg, Laura K. ;
Holland, Ricky D. ;
Li, Donghui ;
Dragan, Yvonne .
METABOLOMICS, 2006, 2 (03) :125-134
[5]   Detection and quantification of d-glucuronic acid in human bile using 1H NMR spectroscopy: relevance to the diagnosis of pancreatic cancer [J].
Bezabeh, Tedros ;
Ijare, Omkar B. ;
Albiin, Nils ;
Arnelo, Urban ;
Lindberg, Bo ;
Smith, Ian C. P. .
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2009, 22 (05) :267-275
[6]  
Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802
[7]   Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis [J].
Fang, Fang ;
He, Xinhong ;
Deng, Huiwen ;
Chen, Qun ;
Lu, Jianping ;
Spraul, Manfred ;
Yu, Yihua .
CANCER SCIENCE, 2007, 98 (11) :1678-1682
[8]  
Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333
[9]   HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES [J].
GORDON, DJ ;
PROBSTFIELD, JL ;
GARRISON, RJ ;
NEATON, JD ;
CASTELLI, WP ;
KNOKE, JD ;
JACOBS, DR ;
BANGDIWALA, S ;
TYROLER, HA .
CIRCULATION, 1989, 79 (01) :8-15
[10]  
Hruban RH, 2000, CLIN CANCER RES, V6, P2969